4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · IEX Real-Time Price · USD
18.20
-8.55 (-31.96%)
At close: Jul 17, 2024, 4:00 PM
18.32
+0.12 (0.66%)
Pre-market: Jul 18, 2024, 4:32 AM EDT

4D Molecular Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year Ending
CurrentDec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020
Market Capitalization
941866719705988
Market Cap Growth
177.60%20.40%2.03%-28.62%-
Enterprise Value
429593522474711
PE Ratio
--8.59-6.69-9.89-17.43
PS Ratio
46.0141.80229.9339.0972.58
PB Ratio
1.572.813.112.213.85
P/FCF Ratio
-19.96-11.03-7.32-9.01-19.03
P/OCF Ratio
-20.60-11.43-8.30-10.20-19.41
EV/Sales Ratio
20.9928.60166.8326.2752.25
EV/EBITDA Ratio
-10.89-6.23-5.04-6.94-12.87
EV/EBIT Ratio
-10.27-5.88-4.86-6.64-12.54
EV/FCF Ratio
-13.52-7.54-5.31-6.06-13.70
Debt / Equity Ratio
0.020.050.070.05-
Debt / EBITDA Ratio
-0.14-0.15-0.16-0.24-
Debt / FCF Ratio
-0.18-0.19-0.16-0.21-
Quick Ratio
32.0615.2113.5815.1716.62
Current Ratio
32.6515.6514.0215.6916.88
Asset Turnover
0.050.060.010.060.08
Return on Equity (ROE)
-26.70%-34.10%-40.90%-27.80%-61.80%
Return on Assets (ROA)
-24.80%-31.10%-36.80%-25.50%-32.70%
Return on Capital (ROIC)
-19.67%-35.00%-44.46%-21.26%-22.10%
Earnings Yield
-11.11%-11.64%-14.94%-10.11%-5.74%
FCF Yield
-8.44%-9.07%-13.65%-11.10%-5.25%
Buyback Yield / Dilution
-50.57%-20.95%-16.66%-331.23%-25.05%
Total Shareholder Return
-50.57%-20.95%-16.66%-331.23%-25.05%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).